Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer


A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.




Chemoresponse assays (lab test) measure the effect that chemotherapy treatment has on a patient`s cancer cells in the lab. This test has shown success in a retrospective study in predicting how an individual patient`s tumor will respond to a given chemotherapy and how treatment utilizing an agent that the test said that a patient`s cells would be sensitive too corresponds to a longer progression free interval. This study will determine the ability of two tests used to predict the success of chemotherapy in recurrent, persistent, or refractory cancer of the ovaries, fallopian tube(s) or peritoneum by measuring how long patients live without progression.

Study Status: Terminated


Condition Intervention Phase
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms
n/a N/A

Verified by Precision Therapeutics October, 2012

Sponsored by: Precision Therapeutics
Information provided by: Precision Therapeutics identifier: NCT00288275

Study Type: Interventional

Study Design: Observational Model: Case-Only, Time Perspective: Prospective

Cleveland Clinic
Cleveland, Ohio 44195
United States

Thomas J Rutherford, MD., Principal Investigator
Hong Ma, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site